Table 3.
Efficacy simulation of currently used medicines in AAnetwork
| Inhibitor | Relative IC50 | Inhibition of PGE2 (%) | Inhibition of LTB4 (%) | [PGI2]/[TXA2] |
|---|---|---|---|---|
| Control | — | — | — | 0.6817 |
| Aspirin | IC50(COX-1:COX-2)=0.01 | 90.0 | — | 5.1947 |
| Ibuprofen | IC50(COX-1:COX-2)=0.5 | 90.0 | — | 3.5599 |
| Naproxen | IC50(COX-1:COX-2)=0.7 | 90.0 | — | 2.2915 |
| 6-MNA | IC50(COX-1:COX-2)=1.5 | 90.0 | — | 2.2334 |
| Acetaminophen | IC50(COX-1:COX-2)=1.6 | 90.0 | — | 2.1574 |
| Indomethacin | IC50(COX-1:COX-2)=1.9 | 90.0 | — | 1.9613 |
| Meloxicam | IC50(COX-1:COX-2)=18 | 90.0 | — | 0.5335 |
| Nimesulide | IC50(COX-1:COX-2)=19 | 90.0 | — | 0.5207 |
| Diclofenac | IC50(COX-1:COX-2)=29 | 90.0 | — | 0.4399 |
| Celecoxib | IC50(COX-1:COX-2)=30 | 90.0 | — | 0.4347 |
| Rofecoxib (VIOXX) | IC50(COX-1:COX-2)=267 | 90.0 | — | 0.2804 |
| Licofelone | IC50(5-LOX)=0.18 μM IC50(COX-2)=0.21 μM IC50(COX-1)=1 μM | 96.5 | 90.0 | 0.6983 |
The same parameter set as in Table I and Figure 3 was used here. The ratio of PGI2/TXA2 the reflects possible side effects of the drug. After taking the medicine, if PGI2/TXA2 becomes much larger than the normal level, bleeding side effects may occur. If PGI2/TXA2 decreases significantly, cardiovascular risks will be raised.